$NRIX insider trading
Over the last 12 months, Nurix Therapeutics insiders reported no purchases and 32 sales totaling $4.5M across SEC Form 4 filings. 62% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $4.5M 32 events
- Events · 12m
- 32 Form 4 filings, grouped
- Insiders · 12m
- 3 distinct reporters
- 10b5-1 share
- 62% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | Ring ChristineChief Legal Officer · O | ▼ Sale | 5,787 | $25.76 | $149K | -38.8% | plan · 2 tranches |
| Sep 1, 2026 | Hansen GwennChief Scientific Officer · O | ▼ Sale | 1,452 | $25.47 | $37K | -1.2% | plan |
| Aug 5, 2026 | Hansen GwennChief Scientific Officer · O | ▼ Sale | 4,356 | $25 | $109K | -3.6% | plan |
| Aug 4, 2026 | Hansen GwennChief Scientific Officer · O | ▼ Sale | 4,111 | $24.36 | $100K | -3.4% | plan · 2 tranches |
| Aug 4, 2026 | van Houte HansChief Financial Officer · O | ▼ Sale | 4,761 | $24.36 | $116K | -10.6% | plan · 2 tranches |
| Aug 3, 2026 | Ring ChristineChief Legal Officer · O | ▼ Sale | 16,589 | $23.05 | $382K | -64.6% | plan |
| Jul 30, 2026 | van Houte HansChief Financial Officer · O | ▼ Sale | 2,845 | $23.38 | $67K | -6% | — |
| Jul 30, 2026 | Ring ChristineChief Legal Officer · O | ▼ Sale | 3,847 | $23.38 | $90K | -16.2% | — |
| Jul 30, 2026 | Hansen GwennChief Scientific Officer · O | ▼ Sale | 3,847 | $23.38 | $90K | -3.1% | — |
| Jul 2, 2026 | Ring ChristineChief Legal Officer · O | ▼ Sale | 11,008 | $23.56 | $259K | -44.8% | plan |
| Jun 25, 2026 | Hansen GwennChief Scientific Officer · O | ▼ Sale | 5,394 | $20 | $108K | -4.5% | plan |
| Jun 25, 2026 | Ring ChristineChief Legal Officer · O | ▼ Sale | 28,935 | $20.06 | $581K | -68.1% | plan |
| Jun 2, 2026 | Ring ChristineChief Legal Officer · O | ▼ Sale | 8,148 | $16.6 | $135K | -37.5% | plan |
| May 5, 2026 | van Houte HansChief Financial Officer · O | ▼ Sale | 14,055 | $16.6 | $233K | -27.2% | plan · 2 tranches |
| May 4, 2026 | Ring ChristineChief Legal Officer · O | ▼ Sale | 8,148 | $16.96 | $138K | -30.8% | plan |
| May 1, 2026 | Ring ChristineChief Legal Officer · O | ▼ Sale | 5,394 | $16.76 | $90K | -16.9% | plan |
| Apr 30, 2026 | van Houte HansChief Financial Officer · O | ▼ Sale | 2,388 | $16.65 | $40K | -4.4% | — |
| Apr 30, 2026 | Ring ChristineChief Legal Officer · O | ▼ Sale | 3,214 | $16.65 | $53K | -9.2% | — |
| Apr 30, 2026 | Hansen GwennChief Scientific Officer · O | ▼ Sale | 3,214 | $16.65 | $53K | -2.6% | — |
| Apr 2, 2026 | Ring ChristineChief Legal Officer · O | ▼ Sale | 8,148 | $15.24 | $124K | -23.5% | plan |
| Mar 2, 2026 | Ring ChristineChief Legal Officer · O | ▼ Sale | 8,148 | $15.44 | $126K | -19.1% | plan |
| Feb 9, 2026 | Ring ChristineChief Legal Officer · O | ▼ Sale | 14,261 | $16.66 | $238K | -25% | plan |
| Jan 30, 2026 | van Houte HansChief Financial Officer · O | ▼ Sale | 3,661 | $16.6 | $61K | -7.5% | 2 tranches |
| Jan 30, 2026 | Ring ChristineChief Legal Officer · O | ▼ Sale | 4,421 | $16.6 | $73K | -7.2% | 2 tranches |
| Jan 30, 2026 | Hansen GwennChief Scientific Officer · O | ▼ Sale | 4,895 | $16.6 | $81K | -5.5% | 2 tranches |
| Jan 20, 2026 | Ring ChristineChief Legal Officer · O | ▼ Sale | 3,760 | $18.42 | $69K | -6.9% | plan |
| Dec 18, 2025 | Ring ChristineChief Legal Officer · O | ▼ Sale | 3,760 | $17.9 | $67K | -6.9% | plan · 2 tranches |
| Nov 24, 2025 | Ring ChristineChief Legal Officer · O | ▼ Sale | 37,600 | $17.07 | $642K | -42.5% | plan |
| Nov 3, 2025 | van Houte HansChief Financial Officer · O | ▼ Sale | 6,284 | $12.56 | $79K | -14.3% | plan |
| Oct 30, 2025 | van Houte HansChief Financial Officer · O | ▼ Sale | 3,130 | $12.8 | $40K | -6.7% | — |
| Oct 30, 2025 | Ring ChristineChief Legal Officer · O | ▼ Sale | 3,644 | $12.8 | $47K | -6.7% | — |
| Oct 30, 2025 | Hansen GwennChief Scientific Officer · O | ▼ Sale | 4,087 | $12.8 | $52K | -5.1% | — |
Every $NRIX filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Nurix Therapeutics filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $NRIX feed.